Golimumab as Rescue Therapy for Refractory Immune-Mediated Uveitis: A Three-Center Experience
Objective. To evaluate, in three Spanish tertiary referral centres, the short-term safety and efficacy of golimumab (GLM) for treatment of immune-mediated uveitis resistant to previous immunosuppressive therapy. Methods. Nonrandomized retrospective interventional case series. Thirteen patients with...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2014-01-01
|
| Series: | Mediators of Inflammation |
| Online Access: | http://dx.doi.org/10.1155/2014/717598 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850228378578190336 |
|---|---|
| author | Miguel Cordero-Coma Vanesa Calvo-Río Alfredo Adán Ricardo Blanco Carolina Álvarez-Castro Marina Mesquida Sara Calleja Miguel A. González-Gay José G. Ruíz de Morales |
| author_facet | Miguel Cordero-Coma Vanesa Calvo-Río Alfredo Adán Ricardo Blanco Carolina Álvarez-Castro Marina Mesquida Sara Calleja Miguel A. González-Gay José G. Ruíz de Morales |
| author_sort | Miguel Cordero-Coma |
| collection | DOAJ |
| description | Objective. To evaluate, in three Spanish tertiary referral centres, the short-term safety and efficacy of golimumab (GLM) for treatment of immune-mediated uveitis resistant to previous immunosuppressive therapy. Methods. Nonrandomized retrospective interventional case series. Thirteen patients with different types of uveitis that were resistant to treatment with at least 2 previous immunosuppressors were included in this study. All included patients were treated with GLM (50 mg every four weeks) during at least 6 months. Clinical evaluation and treatment-related side effects were assessed at least four times in all included patients. Results. Eight men and 5 women (22 affected eyes) with a median age of 30 years (range 20–38) and active immune-mediated uveitides were studied. GLM was used in combination with conventional immunosuppressors in 7 patients (53.8%). GLM therapy achieved complete control of inflammation in 12/13 patients (92.3%) after six months of treatment. There was a statistically significant improvement in mean BCVA (0.60 versus 0.68, P=0.009) and mean 1 mm central retinal thickness (317 versus 261.2 μ, P=0.05) at the six-month endpoint when compared to basal values. No major systemic adverse effects associated with GLM therapy were observed. Conclusions. GLM is a new and promising therapeutic option for patients with severe and refractory uveitis. |
| format | Article |
| id | doaj-art-1e81994fa57f4eacb3c66d587efceb43 |
| institution | OA Journals |
| issn | 0962-9351 1466-1861 |
| language | English |
| publishDate | 2014-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Mediators of Inflammation |
| spelling | doaj-art-1e81994fa57f4eacb3c66d587efceb432025-08-20T02:04:33ZengWileyMediators of Inflammation0962-93511466-18612014-01-01201410.1155/2014/717598717598Golimumab as Rescue Therapy for Refractory Immune-Mediated Uveitis: A Three-Center ExperienceMiguel Cordero-Coma0Vanesa Calvo-Río1Alfredo Adán2Ricardo Blanco3Carolina Álvarez-Castro4Marina Mesquida5Sara Calleja6Miguel A. González-Gay7José G. Ruíz de Morales8Department of Ophthalmology, University Hospital of León, 24071 León, SpainDepartment of Rheumatology, University Hospital “Marques de Valdecilla”, IFIMAV, 39008 Santander, SpainDepartment of Ophthalmology, University Hospital “Clínic”, 08036 Barcelona, SpainDepartment of Rheumatology, University Hospital “Marques de Valdecilla”, IFIMAV, 39008 Santander, SpainDepartment of Rheumatology, University Hospital of León, 24071 León, SpainDepartment of Ophthalmology, University Hospital “Clínic”, 08036 Barcelona, SpainUveitis Unit, University Hospital of León, 24071 León, SpainDepartment of Rheumatology, University Hospital “Marques de Valdecilla”, IFIMAV, 39008 Santander, SpainUveitis Unit, University Hospital of León, 24071 León, SpainObjective. To evaluate, in three Spanish tertiary referral centres, the short-term safety and efficacy of golimumab (GLM) for treatment of immune-mediated uveitis resistant to previous immunosuppressive therapy. Methods. Nonrandomized retrospective interventional case series. Thirteen patients with different types of uveitis that were resistant to treatment with at least 2 previous immunosuppressors were included in this study. All included patients were treated with GLM (50 mg every four weeks) during at least 6 months. Clinical evaluation and treatment-related side effects were assessed at least four times in all included patients. Results. Eight men and 5 women (22 affected eyes) with a median age of 30 years (range 20–38) and active immune-mediated uveitides were studied. GLM was used in combination with conventional immunosuppressors in 7 patients (53.8%). GLM therapy achieved complete control of inflammation in 12/13 patients (92.3%) after six months of treatment. There was a statistically significant improvement in mean BCVA (0.60 versus 0.68, P=0.009) and mean 1 mm central retinal thickness (317 versus 261.2 μ, P=0.05) at the six-month endpoint when compared to basal values. No major systemic adverse effects associated with GLM therapy were observed. Conclusions. GLM is a new and promising therapeutic option for patients with severe and refractory uveitis.http://dx.doi.org/10.1155/2014/717598 |
| spellingShingle | Miguel Cordero-Coma Vanesa Calvo-Río Alfredo Adán Ricardo Blanco Carolina Álvarez-Castro Marina Mesquida Sara Calleja Miguel A. González-Gay José G. Ruíz de Morales Golimumab as Rescue Therapy for Refractory Immune-Mediated Uveitis: A Three-Center Experience Mediators of Inflammation |
| title | Golimumab as Rescue Therapy for Refractory Immune-Mediated Uveitis: A Three-Center Experience |
| title_full | Golimumab as Rescue Therapy for Refractory Immune-Mediated Uveitis: A Three-Center Experience |
| title_fullStr | Golimumab as Rescue Therapy for Refractory Immune-Mediated Uveitis: A Three-Center Experience |
| title_full_unstemmed | Golimumab as Rescue Therapy for Refractory Immune-Mediated Uveitis: A Three-Center Experience |
| title_short | Golimumab as Rescue Therapy for Refractory Immune-Mediated Uveitis: A Three-Center Experience |
| title_sort | golimumab as rescue therapy for refractory immune mediated uveitis a three center experience |
| url | http://dx.doi.org/10.1155/2014/717598 |
| work_keys_str_mv | AT miguelcorderocoma golimumabasrescuetherapyforrefractoryimmunemediateduveitisathreecenterexperience AT vanesacalvorio golimumabasrescuetherapyforrefractoryimmunemediateduveitisathreecenterexperience AT alfredoadan golimumabasrescuetherapyforrefractoryimmunemediateduveitisathreecenterexperience AT ricardoblanco golimumabasrescuetherapyforrefractoryimmunemediateduveitisathreecenterexperience AT carolinaalvarezcastro golimumabasrescuetherapyforrefractoryimmunemediateduveitisathreecenterexperience AT marinamesquida golimumabasrescuetherapyforrefractoryimmunemediateduveitisathreecenterexperience AT saracalleja golimumabasrescuetherapyforrefractoryimmunemediateduveitisathreecenterexperience AT miguelagonzalezgay golimumabasrescuetherapyforrefractoryimmunemediateduveitisathreecenterexperience AT josegruizdemorales golimumabasrescuetherapyforrefractoryimmunemediateduveitisathreecenterexperience |